Suggestions
Sanket Agrawal
CEO, 1859 | Growth Driver & Builder
Sanket Agrawal is a dynamic senior biopharmaceutical leader with a track record of delivering value and mission-critical outcomes in his field. He has experience in advancing novel therapies, leading cross-functional teams, and building sustained winning cultures. Sanket has a diverse background that integrates biopharma drug development and commercialization, organization scaling and transformation, and AIML/Big-Data/Digital. He graduated with a B. Eng. in Delhi College of Engineering, an M. Eng. at the University of Toronto, an MPH at the University of Liverpool, and an MBA at the University of California, Los Angeles - The Anderson School of Management.
Sanket has held various executive-level positions throughout his career at Amgen, Relsys International, Deloitte Consulting, and Accenture. He is currently the Global Product General Manager of Oncology at Amgen, leading the KRAS Franchise-Sotorasib. Notably, he has also served as Head of Global Commercial, Oncology/Hematology Pipeline, Global Commercial Lead of Oncology, Executive Director of Strategy and Operations (R&D/Regulatory), Chief Business Officer at Relsys International (Oracle Health Sciences), and VP/GM at Relsys International (Oracle Health Sciences). He also co-founded and was principal of SAVtech Solutions.
Sanket is a lifelong learner, entrepreneur, and compassionate, empowering leader, with a proven ability to succeed across boundaries and roles. He has repeatedly built "new oncology" franchises, immuno and precision - leveraging diagnostics, novel trials, fast-to-market, and business development while optimizing science, speed, and the market. He has also delivered robust commercial results, including portfolio strategy, new product planning, brand positioning, value, innovative go-to-market models, financial, and operational performance.
Highlights
Leaving #JPM24 with a sense of cautious optimism and a resilient community. It was invigorating to meet partners, investors, colleagues and friends. The takeaway was clear: 2024 will continue to challenge us, but good #science, #innovation, and solid execution will be rewarded.
The promise of #AI is real across bench-to-bedside, and as we engaged in exciting sessions at #AAIH, #WuXi Global Forum, #Nvidia and many others, the value of high-quality training and testing #data resonated as a consistent theme. Outputs are only as good as real, empirical datasets that train models.
Our team left with refreshed purpose and energy to push our novel data-first-AIML #drugdiscovery platform even further to identify and generate molecules that can become medicines fast. #Patients are waiting, let's #bebold.
Excellent article underscoring that AI models are only as good as the data used to train them. Federated datasets can overcome challenges in data-scarce domains, but should be generated under comparable conditions. We are generating volumes of data under consistent conditions so AIML can learn the bioactivity ‘profiles’ of diverse targets across large chemical spaces. As a result, we'll have the ability to generalize to novel targets and compounds.
We'd love to explore more avenues to cooperatively share quality data which ultimately benefit patients. Let's talk.
https://lnkd.in/gBZMxDfv
1859 #AIRevolution #DrugDiscovery #MachineLearning #PowerofData
